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background: Single embryo transfer (SET) provides the most certain means to reduce the risk of multiple gestation. Regrettably, pro-
spective trials of SET have demonstrated reductions in per-cycle delivery rates. A validated method of comprehensive chromosome screening
(CCS) has the potential to optimize SET by transferring only euploid embryos. This retrospective study evaluates the efﬁcacy of SET with
CCS in an infertile population.
methods: Overall and age-controlled ongoing pregnancy rates (OPR) were compared between women undergoing SET following CCS
(CCS-SET, n ¼ 140) and those undergoing SET without aneuploidy screening (control SET, n ¼ 182). All transfers were at the blastocyst
stage, with CCS performed after trophectoderm biopsy of expanded blastocysts and analysis with rapid PCR allowing for fresh transfer.
results: In the CCS-SET and control SET groups, an OPR of 55.0 and 41.8%, respectively, was obtained. The OPR was lower for the
control group (P , 0.01) despite a younger age than the CCS group (37.3+3.4 versus 34.2+3.9 years; P , 0.001). Birthweight and ges-
tational age at delivery were equivalent. The proportion of clinical pregnancies resulting in miscarriage was higher in the control group (24.8
versus 10.5%, P , 0.01), with more patients requiring surgical interventions for aneuploid pregnancies. There was one monozygotic twin
delivery in the CCS group and none in the control group.
conclusions: Compared with traditional blastocyst SET, SET after trophectoderm biopsy and rapid PCR-based CCS increases OPR
and reduces the miscarriage rate. The enhanced selection empowered by CCS with SET may provide a practical way to eliminate multi-
zygotic multiple gestation without compromising clinical outcomes per cycle.
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Introduction
Multiple gestation is the principal complication of IVF, causing
increased maternal and neonatal morbidity compared with singleton
pregnancies (Reddy et al., 2007). Though single embryo transfer
(SET) has been recommended as the most certain way to minimize
the risk of twins, the practice is still rare, accounting for only 12% of
embryo transfers in the USA (Centers for Disease Control and
Prevention, 2009). Furthermore, the recommendation for SET
applies to young, good-prognosis patients, generally ,35 years old
(Practice Committee of the Society for Assisted Reproductive
Technology and Practice Committee of the American Society for
Reproductive Medicine, 2009). A recent meta-analysis of prospective
studies comparing SET with double embryo transfer (DET) showed a
signiﬁcant decrease in live birth rates per transfer from SET (42.7
versus 26.3%, P , 0.00001) (Pandian et al., 2009) among good-
prognosis patients. There is a paucity of data on the efﬁcacy of SET
in an older, poorer prognosis IVF population but the diminution in out-
comes is likely to persist. Women over 35 years of age still have a
signiﬁcant risk of twin pregnancy when they do conceive after IVF or
ICSI and they also stand to beneﬁt from singleton pregnancies resulting
from SET.
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miscarriage (Nasseri et al., 1999; Bettio et al., 2008; Scott et al.,
2008); therefore, it is logical to propose that preimplantation genetic
screening (PGS) can improve selection for SET. It is of paramount
importance that the method of PGS is accurate and that the technique
itself does not diminish the developmental potential of the individual
embryo tested (Scott and Treff, 2010). Experience has shown that
ﬂuorescence in situ hybridization (FISH)-based PGS is inaccurate and
not beneﬁcial (Practice Committee of the Society for Assisted Repro-
ductive Technology and Practice Committee of the American Society
for Reproductive Medicine, 2007; Fritz, 2008). Using aneuploidy
screening to aid in selection for SET has not been studied using the
newer, validated methods of comprehensive chromosome screening
(CCS) that can be performed at the blastocyst stage after trophecto-
derm biopsy, testing all 24 chromosomes (Treff et al., 2010). In this
study, we compared outcomes from traditional blastocyst-stage SET
(control SET) with outcomes after SET of a euploid blastocyst
screened with PCR-based CCS (CCS-SET).
Materials and Methods
All SETs performed at Reproductive Medicine Associates of New Jersey,
NJ, USA, between 1 January 2010 and 30 June 2011 were included in
the analysis. Transfers of embryos originating from oocyte donation
cycles were excluded. Patients who required preimplantation genetic diag-
nosis for single-gene defects were also excluded as this introduces an
additional selection bias. Cycles in which previously frozen embryos
were thawed for rapid PCR and same-day transfer were also excluded.
Both elective and non-elective SETs were included, as were fresh and
frozen SETs. Only the ﬁrst SET during the time period was included for
patients who had more than one SET performed.
In both groups, gonadotrophin dosing, stimulation and monitoring of the
IVF cycle were per practice routine. Patients underwent controlled ovarian
hyperstimulation (COH) generally using a step-down protocol, with a
typical starting dose of 150–450 IU/day of recombinant FSH combined
with either 75–150 IU/day of human menopausal gonadotrophins or
10–20 IU/day of low-dose hCG. The main methods of COH were
GnRH agonist down-regulation during the luteal phase of the prior
menstrual cycle or intracycle GnRH antagonist administration.
Day 3 FSH was determined on all patients prior to cycling. Although a
value of 17 mIU/l or greater is considered abnormal in the Reproductive
Medicine Associates of New Jersey laboratory, patients were not pre-
vented from cycling if they had values above this range. Patients were
only taken to oocyte retrieval if they had four or more mature follicles
(≥14 mm diameter) on the day of hCG administration. Per laboratory
routine, the entire cohort of embryos was placed in extended culture if
there were at least four embryos on Day 3 of development with ≥4
cells and ≤30% embryo fragmentation. Patients who elected to perform
CCS or elected to have SET had all embryos placed in extended
culture, regardless of the number available on Day 3.
Patients were offered CCS if they were of advanced age (.35 years
old), had a previous failed IVF cycle, had a history of recurrent pregnancy
loss or they wanted to optimize outcomes with SET. The CCS technology
was developed and offered clinically using an Institutional Review
Board-approved protocol. Patients signed an informed consent form
describing the methodology and limitations of CCS.
In the CCS group, all oocytes were fertilized with ICSI. On Day 3 of
development, an infrared diode laser was used to create a small breech
in the zona pellucida prior to placing the embryos in extended culture.
Laser biopsy was then performed on all expanded blastocysts (Gardner
grades 3–6) of sufﬁcient quality by removing  5 trophectoderm cells
that had herniated through the breech in the zona (Gardner and School-
craft, 1999). After lysis of the trophectoderm cells as previously described
(Treff et al., 2009a,b), DNA was ampliﬁed and characterized using quan-
titative real-time PCR (qPCR) (Treff et al., 2012). Preampliﬁcation of 96
loci from embryo biopsy lysates was conducted in a 50 ml reaction
volume containing 10 ml of lysate, 25 ml of TaqMan PreAmp Master Mix
(Applied Biosystems, Foster City, CA, USA), 12.5 ml of primer pool
(10 mM of each primer pair) and 2.5 ml of molecular biology grade
water, and the following conditions; 10 min at 958C, 18 cycles of 958C
for 15 s and 608C for 4 min and held at 48C, using an ABI 2700 thermal-
cycler. The PreAmp reaction was then diluted in 1.25 ml of Gene Expres-
sion Master Mix (Applied Biosystems) and 1.2 ml of molecular biology
grade water. Four replicate 5 ml qPCR using each individual primer pair
were then performed on an ABI 7900 thermalcycler as recommended
by the manufacturer for relative quantiﬁcation (Applied Biosystems). The
copy number for all 22 pairs of autosomes and two sex chromosomes
was assigned using standard methods of relative quantiﬁcation (Schmittgen
and Livak, 2008) where the average threshold cycle (CT) of all of the auto-
somes (excluding the chromosome under evaluation) served as the
endogenous control data for the average CT of the four assays of each indi-
vidual chromosome under evaluation (DCT), and known normal male
sample results were used as the reference data to normalize DCT data
from each embryo biopsy (DDCT).
This PCR methodology demonstrated 98.6% accuracy in preclinical
studies (Treff et al., 2009a,b) and improvement in clinical outcomes in
preliminary results of an RCT (Scott et al., 2010a,b). Only embryos diag-
nosed as 46XX or 46XY with sufﬁcient conﬁdence were suitable for
transfer or cryopreservation. The best euploid embryo, in terms of
morphology, was selected for transfer in the CCS-SET group. Super-
numerary euploid embryos were vitriﬁed and warmed for subsequent
frozen transfers. In the control SET group, the morphologically best
quality embryo available was selected for transfer.
All transfers occurred at the blastocyst stage either in the afternoon of
the ﬁfth day or the morning of the sixth day of embryo development after
oocyte retrieval. Fresh CCS-SETs all occurred on the morning of Day 6, as
trophectoderm biopsies were performed on Day 5 with rapid PCR per-
formed overnight. Frozen embryo transfers (FETs) included both natural
and programmed cycles and were performed 5 days after ovulation or
the initiation of a vaginal progesterone suppository (Endometrin, Ferring
Pharmaceuticals; Parsippany, NJ, USA) or i.m. progesterone in oil. All
transfers were performed in the same manner, using a soft Wallace
transfer catheter and abdominal ultrasound guidance.
A pregnancy test was performed 8 or 9 days after transfer. Serial ultra-
sound monitoring was performed until 8–9 weeks gestation, at which time
patients were discharged to obstetrical care. Follow up of all pregnancies
was performed to determine live birth and ongoing pregnancy rates
(OPR). A clinical pregnancy was deﬁned as the presence of an intrauterine
gestational sac on ultrasound. The OPR was deﬁned as live births plus sus-
tained pregnancies (beyond the ﬁrst trimester) per embryo transferred.
Statistical analysis was performed using Open Epi Version 2.3.1 (www.
openepi.com). Chi-square and Fisher’s exact test was applied for categor-
ical variables and unpaired t-test was applied for interval variables. Statis-
tical signiﬁcance was set at P , 0.05.
Results
In the CCS-SET group, there were 140 patients. In the control SET
group, there were 182 patients. Patient demographics are summarized
in Table I. Of note, the CCS-SET group was older (37.3 versus 34.2
years old, P , 0.001) and had more prior miscarriages and IVF
1218 Forman et al.cycles. Cycle-speciﬁc embryology outcomes are summarized in
Table II.
PregnancyoutcomesaresummarizedinTableIII.TheCCS-SETgroup
demonstratedahigherOPRthanthecontrolSETgroup.Figure1shows
OPR stratiﬁed by age group with the CCS-SET group demonstrating a
higher OPR in the ,35 year old and .40 year old categories and a
trend toward higher OPR for age 38–40 years.
The clinical miscarriage rate was lower after CCS-SET than control
SET (P , 0.01). Among patients with clinical miscarriages, 14 out of 25
patients in the control group required dilation and curettage (D&C)
with 8 out of 11 villous samples demonstrating aneuploidy by conven-
tional karyotyping. In contrast, three out of nine patients with a clinical
miscarriage in the CCS-SET group required D&C. One villous
specimen was found to have a de novo balanced translocation. The
risk of a clinical pregnancy resulting in a D&C was reduced after
CCS (13.9 versus 3.4%, P ¼ 0.02).
To date, there have been 63 deliveries in the control group and 49
in the CCS-SET group. Birthweights between groups were equivalent
(Table III). There was one delivery prior to 32 weeks gestation in each
group and no major congenital anomalies have been reported to date
.............................................................................................................................................................................................
Table III Pregnancy outcomes by treatment group.
Control SET CCS-SET
Chemical pregnancy rate 108/182 (59.3%) 96/140 (68.6%) P ¼ 0.04*
Ongoing pregnancy rate 76/182 (41.8%) 77/140 (55.0%) P , 0.01*
Clinical miscarriage rate 25/101 (24.8%) 9/86 (10.5%) P , 0.01*
Monozygotic twin rate 0/76 (0%) 1/77 (1.3%) P ¼ 0.5
†
Gestational age at delivery (weeks+SD) 38.9+1.4 38.6+2.0 P ¼ 0.4
‡
Birthweight (grams+SD) 3286+522 3281+525 P . 0.9
‡
*Chi-square.
†Fisher’s exact test.
‡t-test.
.............................................................................................................................................................................................
Table II Cycle outcomes according to treatment group.
Control SET CCS-SET
Estradiol on day of hCG (mean+SD) 2049+1151 pg/ml 2187+1246 pg/ml P ¼ 0.3*
Oocytes retrieved (mean+SD) 14.9+9.6 15.9+10.0 P ¼ 0.4*
Number of 2PNs (mean+SD) 9.0+6.5 9.9+6.4 P ¼ 0.2*
Number of blastocysts (mean+SD) 3.9+3.6 5.6+3.8 P , 0.01*
Cryopreserved blastocysts (mean+SD) 2.1+2.8 3.1+2.6 P , 0.01*
2PN, two pronuclei.
*t-test.
.............................................................................................................................................................................................
Table I Patient demographics according to treatment group.
Number of patients Control SET CCS-SET
182 140
Age at retrieval (mean+SD) 34.2+3.9 years 37.3+3.4 years P , 0.001*
Maximal Day 3 FSH (mean+SD) 8.2+2.8 mIU/ml 8.1+3.3 mIU/ml P ¼ 0.8*
Prior pregnancies (mean+SD) 1.4+1.3 1.9+1.7 P ¼ 0.003*
Prior deliveries (mean+SD) 0.7+0.7 0.7+0.9 P . 0.9*
Prior miscarriages (mean+SD) 0.5+0.8 0.8+1.7 P ¼ 0.04*
Prior COH/IUI cycles (mean+SD) 0.7+1.3 0.7+1.5 P . 0.9*
Prior IVF cycles (mean+SD) 1.1+1.1 1.8+1.6 P , 0.001*
Prior FETs (mean+SD) 0.3+0.7 0.3+0.7 P . 0.9*
COH, controlled ovarian hyperstimulation; IUI, intrauterine insemination;
FET, frozen embryo transfer.
*t-test.
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the CCS-SET group and none in the control SET group.
The OPR for fresh transfers and FETs was similar in both groups
(control SET 39.1 versus 44.4%, P ¼ 0.4; CCS-SET 59.7 versus
51.8%, respectively, P ¼ 0.4).
Elective SETs were deﬁned based on the presence of additional
blastocysts that were deemed suitable for cryopreservation. For the
CCS-SET group, an elective SET implies the availability of another
euploid blastocyst. In the CCS-SET, there was no difference in OPR
between elective and non-elective SETs (54.6 versus 56.5%, respect-
ively, P ¼ 0.8), despite an older average age for patients who had
non-elective SETs (36.6 versus 38.1 years, P ¼ 0.01). Among the
control group, elective SET resulted in higher OPRs than non-elective
SET (54.5 versus 32.4%, respectively, P , 0.01), though the average
age was signiﬁcantly younger in the elective SET group (33.1 versus
34.9 years, P , 0.01).
All CCS-SETs were performed on Day 6 of embryo development
because trophectoderm biopsy is only performed at the expanded
blastocyst stage. In the control SET group, 62.6% of patients had trans-
fers of blastocysts that had developed in culture to Day 6. There was
no difference between groups in the proportion of transferred Day 6
blastocysts that were considered high quality with inner cell mass and
trophectoderm grades ≥B (75.4% control SET versus 82.9%
CCS-SET, P ¼ 0.2). The CCS-SET group had 667 blastocysts biopsied
for CCS, with 56.2% being euploid.
Discussion
In the current study, we have reviewed a consecutive series of 140
patients who had SET after the application of clinically indicated
CCS. The OPR of 55.0% surpasses the cumulative live birth rate
after DET in a recent Cochrane Review, despite an average age that
is older than the maximum age enrolled in ﬁve of the six studies
included for analysis (Pandian et al., 2009). In an attempt to assess
the beneﬁt of CCS-SET while correcting for variations in laboratory
and other variables, we compared CCS-SET to all unscreened blasto-
cyst SETs performed in the same programme during the same time
period. The OPR was higher in the CCS-SET than the control SET
group (55.0 versus 41.8%, respectively, P , 0.01) despite an older
age and a history of more prior IVF cycles and miscarriages.
Combining CCS with SET resulted in higher OPRs for every age
group, though owing to the sample size the difference was not statis-
tically signiﬁcant in the 35–37 and 38–40-year-old age groups. The
miscarriage rate was signiﬁcantly reduced by transferring euploid
embryos, despite an older average age in the CCS-SET group. Further-
more, CCS-SET appears to reduce the risk of a clinical pregnancy
resulting in a D&C for an abnormal gestation. Preventing abnormal
pregnancies allows patients to resume treatment more rapidly and
decreases the emotional and ﬁnancial burden of IVF. Performing
trophectoderm biopsy for CCS does not have an effect on the birth-
weight of singletons at delivery, regardless of maternal age. Transfer-
ring only euploid embryos appears to attenuate the age-related
decline in live birth rates and maintains high pregnancy rates even
when there are no other embryos from which to select.
With a retrospective analysis, it is difﬁcult to determine the impact
of trophectoderm biopsy with CCS on delivery rates per cycle
initiated. Most patients utilizing CCS have a poor prognosis and
would plan for a DET if two euploid blastocysts were available.
However, during the same time period at the Reproductive Medicine
Associates of New Jersey, 47 patients had cycles in which all blasto-
cysts biopsied were aneuploid and thus a transfer could not be per-
formed. This represented 8.3% of cycles with biopsy for CCS.
These patients were 40.9+2.9 years old, had 10.7+5.8 oocytes
retrieved and had 1.9+1.0 blastocysts tested. If these 47 patients
were included with the CCS-SET group, the OPR per biopsy cycle
initiated would be 41.2% (77/187). While this is equivalent to the
OPR for the control SET group of 41.8%, the age difference is accen-
tuated between the groups (34.2 versus 38.2 years, P , 0.001).
It also must be noted that while low responders were included in
this study, both groups demonstrated a good response in terms of
Figure 1 OPR by age group for control SET versus CCS-SET.
1220 Forman et al.oocytes retrieved. The number of oocytes retrieved and basal FSH
were similar between groups, so differences in oocyte quantity or
quality cannot explain the improvement in per-transfer OPR with
CCS-SET. As expected given the average age in the CCS group,
43.8% of blastocysts tested with CCS were aneuploid. The transfer
of untested blastocysts that were aneuploid likely explains the
decreased OPR in the control SET group.
The last decade has seen a dramatic reduction in the incidence of
higher-order multiple pregnancies, in large part related to the intro-
duction of extended culture and a reduction in the number of
embryos transferred per cycle. Nevertheless, the rate of IVF twin
pregnancies in the USA remains essentially unchanged at  30%
(Centers for Disease Control and Prevention, 2009). The cost of
caring for preterm babies resulting from IVF multiple gestation is esti-
mated at $1 billion annually in the USA (Bromer et al., 2011).
SET holds the promise of providing patients with a single healthy
child as a result of each IVF cycle. However, there has been a
persistent gap between live birth rates from SET and multiple
embryo transfer. Prospective studies in good-prognosis patients have
shown a lower pregnancy rate per transfer when employing SET.
Although nearly equivalent pregnancy rates have been achieved
when including an additional FET (Thurin et al., 2004), this introduces
additional cost and time to achieve pregnancy. Many patients drop out
of care because of the burden of treatment required by multiple cycles
(Verberg et al., 2008). Owing to the difference in outcomes, most
reproductive endocrinologists do not routinely offer SET to all patients
(Jungheim et al., 2010). Through education and outreach a majority of
good-prognosis patients can be persuaded to accept SET (Ryan et al.,
2007) but many are reluctant to compromise outcomes.
Signiﬁcantimprovementsinembryoselection—allowingtheabilityto
better assess the reproductive potential of an individual embryo—are
required before SET will be considered an acceptable option for all
patients undergoing IVF. An RCT showed that extended culture
improves SET live birth rates compared with cleavage-stage SET (Papa-
nikolaou et al., 2006). With increasing female age, however, the rate of
embryonic aneuploidy increases and a substantial proportion of
morphologically normal blastocysts are chromosomally abnormal
(Scott et al., 2010a,b). An additional selection criteria—beyond blasto-
cyst morphology—is necessary to improve outcomes from SET and
make it a more acceptable option to patients and physicians.
The concept of using PGS to optimize SET selection was previously
attempted with FISH-based aneuploidy screening (Jansen et al., 2008;
Staessen et al., 2008). Both studies were halted prematurely as there
was no beneﬁt in using FISH to optimize SET in patients ,36 or 38
years old. These outcomes likely relate to inherent ﬂaws in FISH-based
PGS and do not necessarily invalidate the concept of using aneuploidy
screening to improve selection for SET.
Over the past few years several new PGS methods have been intro-
duced that offer CCS. In retrospective studies, these technologies
have yielded excellent results in poor-prognosis patients (Schoolcraft
et al., 2010, 2011). An ongoing prospective trial of PCR-based CCS
revealed increased implantation rates after an interim analysis (Scott
et al., 2010b).
Few studies have previously addressed SET in women of advanced
reproductive age. One retrospective study found an OPR of 51.1% in
45 patients over age 35 years (Davis et al., 2008). This older popula-
tion of women stands to beneﬁt from singleton gestation and
prospective data are lacking. Given the age-related increased incidence
of aneuploidy, this group may beneﬁt most from SET with CCS.
The present study, while suggestive of a beneﬁt from CCS, has
several limitations. Given the retrospective nature of this study, the
two groups were not equivalent. Though older, the patients who uti-
lized CCS had more embryos available for biopsy and cryopreserva-
tion. Patients in the control SET group who received non-elective
SETs may represent a poor-prognosis group as they had only one
embryo of sufﬁcient quality to transfer. The groups being compared
may have had different indications for performing SET. On average,
both groups tended to be good responders with good-quality blasto-
cysts from which to select. Patients without any blastocysts available
for transfer would not be able to beneﬁt from CCS-SET. Ongoing
research is aimed at determining the impact of applying this treatment
strategy more broadly to the infertility population.
It is becoming evident that increased application of SET will be
required to reduce the incidence of multiple pregnancy and its compli-
cations. While some countries have instituted mandatory SET policies,
pregnancy rates per transfer are reduced with this strategy and
patients who shoulder the cost of their care remain reluctant to
choose this option. The next major improvement in assisted repro-
duction technology (ART) will be to optimize SET so that high preg-
nancy rates are maintained and the option can be recommended to
patients regardless of their age or previous reproductive history.
While the results of this study are promising, a deﬁnite answer
awaits a prospective comparison of CCS-SET versus contemporary
transfer practice. Such a study is currently underway at the Repro-
ductive Medicine Associates of New Jersey (NCT01408433). Should
level I evidence demonstrate the efﬁcacy of this approach, the result
would be a paradigm shift in ART, with CCS-SET allowing for
greater patient safety by avoiding multiple gestation while maintaining
excellent outcomes and reducing the burden of care for patients and
society.
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